Most COVID-19 vaccines are designed to elicit immune responses, ideally neutralizing
antibodies (NAbs), against the SARS-CoV-2 spike protein. Several vaccines, including …

Background There is emerging evidence of long-term sequelae in a considerable proportion
of COVID-19 patients after recovery and the spectrum and severity of such sequelae should …

More than 190 vaccines are currently in development to prevent infection by the novel
severe acute respiratory syndrome coronavirus 2. Animal studies suggest that while …

The novel coronavirus disease 2019 (COVID-19) pandemic has spread worldwide, and
finding a safe therapeutic strategy and effective vaccine is critical to overcoming severe …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a new virus that has
higher contagious capacity than any other previous human coronaviruses (HCoVs) and …

Several neurological symptoms and complications have been described in association with
COVID-19, such as anosmia, ageusia, encephalitis and Guillain-Barré syndrome. Here, we …

Two years after the appearance of the SARS-CoV-2 virus, the causal agent of the current
global pandemic, it is time to analyze the evolution of the immune protection that infection …

The acute loss of taste and smell following COVID-19 are hallmark symptoms that affect 20–
85% of patients. However, the pathophysiology and potential treatments of COVID-19 smell …

The lung is the primary site of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2)-induced immunopathology whereby the virus enters the host cells by binding to …

The current pandemic caused by the new severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has become a public health emergency. To date, March 1, 2021, coronavirus …